Dr. Laura Horodyski, MD

Dr. Horodyski practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Horodyski's NPI, 1851822498, was assigned on March 24, 2017. Dr. Horodyski graduated from University Of Cincinnati College Of Medicine in 2017. Dr. Horodyski holds Florida license ME163959.

Dr. Horodyski's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Horodyski's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Horodyski is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Horodyski to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Horodyski practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Horodyski's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Horodyski is board certified in urology by the American Board of Urology. Dmand AI has Dr. Horodyski's licenses on file in 2 states: Florida and Pennsylvania.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney removal surgery, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Horodyski treats.

CMS data shows 545 Medicare services from Dr. Horodyski across 7 procedure codes in 2024, for 216 Medicare patients. Medicare paid $31,187 for them. Every service was in an office.

CMS counts 216 Medicare patients who saw Dr. Horodyski in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Horodyski's median patient age at 69, with 17% women.

In 2024, Dr. Horodyski wrote 869 Medicare Part D claims for 241 patients. 77% of them were for generic drugs. CMS names the drug for 730 of them, across 17 drugs with 11 or more claims each, at $157,192 in total drug cost. In 2023, CMS named 573 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Horodyski for performance year 2024, reported as part of a group. Dr. Horodyski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Horodyski as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Horodyski, published from 2017 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Robotic Surgical Procedures. Dr. Horodyski's most frequent co-authors are Ranjith Ramasamy, MD, William Michael Atallah, MD, MPH and Miguel Alfredo Castellan, MD.

CMS Open Payments shows 99 general payments to Dr. Horodyski from 19 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 93% of the total. Boston Scientific Corporation paid the most, $2,924.

Dr. Horodyski graduated from University Of Cincinnati College Of Medicine in 2017.

Dr. Horodyski is in network with 14 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.